Dennis the menace. That's a kids show right Good grief how old are you (I mean the number of years that have passed since you were born, not mentally, mentally I estimate you at 8) are you 12? 13?
Dennis the menace LMAO last time I heard something like that I was 12
Every poster has 15 minutes time to edit a post when he she accidentally posts something.
What counts is the final post and that was without that part as you can find here
But leave it to that frustrated douchebag to twist the words I never used in my final post
The frustration of Anavex runs so high here that now what someone said in an initial post prior to the final post is of life-threatening importance.
lol I will post and stay here as long as I want. Im looking forward to having many pleasant post-exchanges with you hahaha
ooh you are so frustrated about Anavex. How much money did you lose so far? Come on tell us 2 months' salary so $ 2000? 4-month salary so $ 4000
Can't pay the rent to Mommy for you basement anymore ooooh that sucks
I have never said that asswhipe I said this: "Its all about present and future market cap." you added that part and now pretending I said that because you are a loser
link to the post where I said that?
Anyway for your investment ABC: market cap = O/S x stock price
here is my post https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172876605
Why do you ask me? Google it yourself how the market cap of a listed company is calculated. Please report to your elementary school teacher for basic mathematics.
You really are a dumb ass. First, keep denying AVXL changed endpoints then you ask me how a market cap is calculated. I suggest that biotech investment is not for you dummy.
Last-minute changes lead to mixed response for Anavex’s blarcamesine
My advice in my previous post is to wait until after MHRA approval for DCVAXL which I expect half January or before to arrive. That plus some other expected news (such as news about their announced combo trials with upfront payments) should turn NWBO into a minimal x5 bagger so around $5. I can't make any promises for the next few weeks but we are in a nice uptrend which I do not expect to end. UK approval is a given.
I too will buy back into Anavex again on the condition that they have a more clear path for approval. This could mean the FDA-bought-in Anavex SAP for an AD P3 trial on which they are likely to be approved or a journal article outlining how they got the assumption they have met the endpoints. Im not gambling on an AA for AD. If that means I will miss a big bang in AVXL stock in the IMO highly unlikely situation that there will be AA then so be it. Im only investing in nonrevenue biotech companies with a scientifically validated path forward for their drug.
no matter how many times you provide overwelhming evidence exwanneassh the IT guy from Georgia will never admit to anything.
exwanneassh reminds me of Shaggy
She even caught me on camera (It wasn't me)
She saw the marks on my shoulder (It wasn't me)
Heard the words that I told her (It wasn't me)
You are absolutely right this whole instant approval for tissue-agnostic tumors is a figment of ATL's imagination and not based on any FDA regulation outlined here https://www.fda.gov/media/162346/download
Its Atlanta's recurring fantasy based on ChatGTP research.
That article is from Feb 2022.
The point is the trouble that Anavex is in to get AA for this AD trial.
-Changed endpoints late-stage
- No bought-in clear SAP, changing the SAP by every next PR
-Missing a coprimary endpoint which doesn't support the met all primary and secondary endpoints claim (for making that previous statement I personally see Anavex being held legally liable but that is for another discussion)
- Controversial in the manner in which they statistically analyzed the data within the last PR mathematical errors.
- Post hoc data digging
If Anavex's new SAP they have apprearently now decided on since Nov 2022, is accepted by the FDA then their Phase 3 trial has a good chance of being successful.
? sorry I dont understand gibberish. The rest of your post is pure frustration and fantasy.
I have no position in Anavex short or long. But will buy into Anavex after their new SAP as what they appear now (since yesterday's PR) are going for has been bought in by the FDA and they started their P3 AD trial.
This MB is not for anyone to influence anyone else. Its to exchange ideas and discuss the ongoing Anavex trial. My advice to you and any other MB poster is not to be influenced by any other poster but to conduct your own due diligence. Good luck with your investment endeavor.
Just because someone does not post too many times on the Anavex board does not make that person incorrect.
The ongoing OLE will only confirm yesterday called surrogate new endpoints. You can make the illations from 100 datasets or 1000 datasets it doesnt matter if these datasets point to the same statistical conclusion of a non-existing SAP. The problem/challenge Anavex is facing right now is best described in this post
No its a genuine investment tip for retail investors. Call me out in 3 to 6 months from now and call me out now if anything I said about Anavex is not based on common sense.
Or are you not in it to make money? Also, you would insult my intelligence if I was under the impression that 5 new retail shareholders would do anything for NWBO stock price. NWBO will see a huge investor between now and 3-4 months and it's not going to be 5 formal Anavex shareholders.
But thank you for contributing this much power to me ;)
I understand its difficult to cope with the situation Anavex finds its self in at present. My recommendation is to sell AVXL and buy all NWBO shares you can get your hands on. You can thank me in 3 to 6 months.
After an incredible return on NWBO shares, you can sell some of those and buy a small portion back in Anavex. I do believe they will get ADD approved if their SAP for the P3 trial is bought in by the FDA and in a few yeard after their P3 trial has been concluded.